NVO shares are under pressure as the market finds its strategic plan insufficiently bold or fast, though technical support exists at $40.

Now let's talk about Novo, formerly known as Novo Nordisk. The company's shares are under pressure this morning. The market appears to be dissatisfied with the plan revealed by Novo regarding its strategy for the next phase.

It is clear that they saw a large demand for their weight loss drug, at least in its early stages. But now, competition has entered this field and captured part of their market share.

But they plan to launch more than five successful drugs by 2025, and achieve about $23 billion in projected sales by 2035. However, it appears once again that the market wants a faster timeline for these products.

This stock has declined, but what is really interesting is , if you look at the $40 level on the monthly chart , you will find that it represents the stock's 200-month moving average .

In fact, the stock hasn't traded below this average since 2004 or 2003, I think. Therefore, there is a technical support level at around $40, although the fundamentals are still relatively weak.

But they are optimistic about some of the drugs they will be releasing soon. They are looking to reach more than 60 million patients globally by 2030, in addition to increasing their manufacturing capacity tenfold to provide oral treatments for obesity to an additional 15 million patients they plan to roll out over the next two years.

So, they have a strategy, but it's not as bold as the market had hoped, and that's why we're seeing stocks decline today.